ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant prostate cancer

Share :
Published: 4 Jun 2024
Views: 46
Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA

Prof Daniel Petrylak speaks to ecancer at ASCO 2024 about initial results from a study into ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor degrader, in metastatic castration-resistant prostate cancer.

He explains that the purpose of this trial was to evaluate ARV-766 in patients who have previously been treated with chemotherapy or next-generation hormones.

Prof Petrylak reports that patients who received ARV-766 had a 43% rate of a 50% prostate-specific antigen (PSA) reduction showing promising activity with the drug also observed as relatively safe.